linjc16/ctgov huggingface dataset:
Adherence to Physiotherapy Scoliosis Specific Exercises in Adolescents With Spine Deformity: Development of a New Questionnaire

Study Overview
=================
Brief Summary
-----------------
This study aims to develop a new instrument capable of providing an efficient measure of the quality and quantity of adherence to Physiotherapy Scoliosis Specific Exercises performed at home by growing patients with spinal deformity undergoing conservative treatment at a specialized institution. The development of a questionnaire in a Rasch environment and specifically developed for this population will ensure greater sensitivity and specificity of the questionnaire.

Official Title
-----------------
Adherence to Physiotherapy Scoliosis Specific Exercises in Adolescents With Spine Deformity: Development of a New Questionnaire

Conditions
-----------------
Adherence, Treatment, Spinal Deformity

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged between 10 and 18 years adolescent idiopathic scoliosis of 10 ° Cobb or more Scheuermann's kyphosis or idiopathic hyperkyphosis prescription of specific exercises Exclusion Criteria: positive neurological evaluation

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adherence to specific physiotherapy exercises<br> | Other: Questionnaire<br>* Adolescents with spinal deformity will be asked to fill out a new questionnaire measuring the quality and quantity of adherence to specific physiotherapy exercises performed at home. Patients will be recruited at an outpatient service dedicated to the treatment of vertebral deformities during the monthly sessions with the physiotherapist<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence to Physiotherapy Scoliosis Specific Exercises | New questionnaire developped to assess quality and quantity of adherence to specific physiotherapy exercises performed at home patients with spinal deformity treated conservatively | through study completion, an average of 1 year |
Clinical Outcome After Treatment of Patellar Fractures With Locking Plates

Study Overview
=================
Brief Summary
-----------------
Depending on the fracture pattern of patellar fractures tension band wiring, interfragmentary screw fixation or combinations are common treatments. But there are several problems associated with these techniques as fracture dislocation or loosening and perforation of the wire. Furthermore an anatomic reduction with stable fixation in comminuted fractures is almost impossible to achieve. A new option in the treatment of patellar fractures is the locking plate osteosynthesis, which provides a more stable fixation and higher mechanical strength in biomechanical tests compared to classic tension band wiring. Due to various screw positioning a stable fixation in comminuted fractures can be achieved and an early functional treatment with full weight bearing reduces the loss of knee-motion. Furthermore a removal of the osteosynthesis seems not to be essential anymore and the blood supply is not to be compromised. Because of the absent of clinical evidence investigators want to evaluate the clinical outcome after locking plate osteosyntheses in patellar fractures and compare patient satisfaction, functional motion, complications and number of revisions with common treatments.

Official Title
-----------------
Clinical Outcome After Treatment of Patellar Fractures With Locking Plates

Conditions
-----------------
Fracture of Patella

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with indication for operative treatment of a patellar fracture sufficient compliance signed patient information Exclusion Criteria: preoperative disease or trauma of the patellar preoperative loss of motion of the knee former operations of the patellar alcohol or drug consumption

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical short-term results | The clinical short-term results after treating a patellar fracture with plate osteosynthesis are evaluated. Therefore functional motion is measured, complications and revision operations reviewed and knee-scores analyzed (Tegner-Score, Lysholm-Score, Kujala-Score, International Knee Documentation Committee - Subjective knee evaluation form). | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical long-term results | Further changes in functional motion and knee-scores are analyzed as well as the occurrence and frequency of complications and revision operations. | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patellar fracture, fracture of patella, patella, locking plate osteosynthesis, osteosynthesis, star-plate, arrow-plate
Eye Movement and Cognitive Dysfunction

Study Overview
=================
Brief Summary
-----------------
There is association between eye movement disorder and cognitive dysfunction. Therefore, utilizing eye movement and screening for cognitive dysfunction is feasible. In the present study, we will develop an artificial intelligence platform to screening for cognitive dysfunction by inspecting the function of eye movement. Futher more, based on the screening results, the platform will offer referral suggestions.

Official Title
-----------------
The Development of an Artificial Intelligence Platform for Screening and Referral of Cognitive Dysfunction

Conditions
-----------------
Eye Movement Disorder, Cognitive Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ①Subjects who are diagnosed as mild cognitive decline, Alzheimer's disease, Vascular dementia, Lewy body dementia, Frontotemporal dementia, other dementia and normal by neurologist. ②Subjects who can cooperate with the inspection. ③Subjects who agree to participate in the study and sign the consent form Exclusion Criteria: ①Subjects who cannot do the inspection. ②Subjects who suffer from diseases that compromise the inspection.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal<br>Subjects over 45 years old without cognitive dysfunction | |
| Mild cognitive decline<br>Subjects who are diagnosed as mild cognitive decline(MCI) according to neurologists. | |
| Alzheimer's disease<br>Subjects who are diagnosed as Alzheimer's disease(AD) according to neurologists. | |
| Vascular dementia<br>Subjects who are diagnosed as vascular dementia(VD) according to neurologists. | |
| Lewy body dementia<br>Subjects who are diagnosed as Lewy body demenita (DLB) according to neurologists. | |
| Frontotemporal dementia<br>Subjects who are diagnosed as Frontotemporal demenita (FD) according to neurologists. | |
| Other dementia<br>Subjects who are diagnosed as dementia but are not as AD, VD, DLB OR FD. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the curve | AUC values for predicting whether subject has cognitive impairment or not | up to 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy, true positive rate, and true negetive rate | The performance of this artificial platform | up to 1 month |
Periosteal Chondrosarcoma: a Single Institution Experience

Study Overview
=================
Brief Summary
-----------------
Periosteal chondrosarcoma is a low-grade, malignant cartilaginous bone neoplasm that arises on the surface of bone, predominantly in the metaphysis of long bones. Periosteal chondrosarcoma is an infrequent chondrosarcoma subtype which accounts for less than 1% of all chondrosarcomas (1) and has a peak incidence in the fourth decade (2). It has a reported incidence of local recurrences of 13-28% and a low metastatic potential, with distant recurrences occurring mostly in lungs (3). Contrary to conventional chondrosarcomas, grading of periosteal chondrosarcomas seems not to predict prognosis. IDH1 and IDH2 mutations, characteristics of central chondromas/chondrosarcomas, have been also found in a subset of periosteal chondrosarcomas (1, 4). These observations are based on the results from smaller series of cases (1, 5, 6), although the impact of histopathological characteristics on survival, local recurrence and metastases should be assessed in larger series of cases. The aim of the present study is to review all the cases with a diagnosis of primary periosteal chondrosarcoma treated at the Rizzoli Institute from 1900 up to 31 December 2019, retrospectively. The study will exam all the clinical, radiological, and histological features of this tumor with regard importance of medullary involvement, the IDH1/2 gene status, the types of treatment, the status of surgical margins, the presence of progression (dedifferentiation) areas and the relationship of these factors to individual outcome.

Official Title
-----------------
Periosteal Chondrosarcoma: a Single Institution Experience

Conditions
-----------------
Periosteal Chondrosarcoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients treated at Rizzoli Institute from 01 Jan 1900 to 31 Dec 2019 Diagnosis of peristeal chondrosarcoma Written informed consent prior to any study-specific analysis and/or data collection Exclusion Criteria: Patients with histological diagnosis different from periosteal chondrosarcoma.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Periosteal Chondrosarcoma: a single institution experience | the IDH1/2 gene status. | act baseline |
Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study

Study Overview
=================
Brief Summary
-----------------
The USAGE study aims at assessing on a long-term period (two years in average) the outcome in clinical or economical term of patients with knee osteoarthritis (OA) treated or not with Synvisc®, in the 1139.4 clinical trial.

Official Title
-----------------
Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study (U.S.A.G.E. Médico-Economique)

Conditions
-----------------
Osteoarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients have already been followed up on a nine-month period in a pragmatic medica-economical clinical trial (BI Trial No.: 1139.4) Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Synvisc®<br> | |
| Usual treatment of knee<br>nonsteroidal antiinflammatory drugs, antalgics | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Lequesne index | assessment of algo-functional severity of pathology | up to 2 years | 
| Change in Womac index | assessment of symptom severity | up to 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medical costs related to knee osteoarthritis |  | up to 2 years |
Ischemia Time and Graft Survival

Study Overview
=================
Brief Summary
-----------------
Study the effect of ischemia time on patient and graft survival.

Detailed Description
-----------------
Study the effect of cold ischemia and warm ischemia on graft function after one year and patient one year survival.

Conditions
-----------------
Liver Transplant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: recipients of living donor liver transplantation Exclusion Criteria: early mortality

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| one year graft survival |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver transplant recipient
Linagliptin in Schizophrenia Patients

Study Overview
=================
Brief Summary
-----------------
Approximately one third of patients with schizophrenia show a poor response to standard treatment with antipsychotic medications. This treatment resistant group of patients represents a major challenge in everyday psychiatry, and consumes a disproportionate amount of time from the clinicians, resulting in considerable costs to the society and government. Anecdotal evidence suggests that the enzyme dipeptidyl peptidase IV (DPPIV) may be altered in patients with schizophrenia, with a higher level DPPIV enzyme activity being noted. We postulate that this may play a role in the neuropathology of schizophrenia patients and by inhibiting the DPPIV enzyme activity with a DPPIV inhibitor such as linagliptin, we will be able to improve and even ameliorate the symptoms of schizophrenic patients. However, until now there have yet any studies on the potential of these inhibitors in schizophrenia patients. A pilot study is thus proposed to evaluate the potential of the DPPIV inhibitor, linagliptin as an adjunct in schizophrenia patients who are non-responsive to treatment, which will establish the feasibility of a larger trial.

Official Title
-----------------
A Pilot Study to Assess the Efficacy of Linagliptin as an Adjunct in Schizophrenia Patients

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Linagliptin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age and above Diagnosis of schizophrenia. Clinically stable antipsychotic regimen for the last 3 months A total score of 80 or greater at baseline on the Positive and Negative Syndrome Scale Competent and willing to provide written, informed consent Exclusion Criteria: History of substance dependence within the past 2 months Existing relevant physical health problems: such as uncontrolled cardiovascular disease and impaired liver/ renal function History of diabetes History of hepatic or biliary diseases / biliary obstruction A serious suicide/homicide risk in the opinion of the investigator Known allergy to linagliptin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Linagliptin<br>Linagliptin daily | Drug: Linagliptin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PANSS Score |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug safety | No of adverse events recorded per patients | 3 months |
Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein Glomerulopathy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the efficacy and safety of immunoadsorption in the treatment of lipoprotein glomerulopathy.

Detailed Description
-----------------
Lipoprotein glomerulopathy is characterized by nephritic syndrome glomerular protein thrombi and lipid abnormalities, particularly with an elevated level of plasma apoprotein E (apoE).There are no efficiency way to treat lipoprotein glomerulopathy. We firstly successfully treat 2 patients by protein A immunoadsorption with remarkable decreased urine protein and reduction of lipoprotein thrombi on repeated renal biopsy.

Official Title
-----------------
Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein

Conditions
-----------------
Treatment

Intervention / Treatment
-----------------
* Procedure: immunoadsorption


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A new diagnosis of lipoprotein glomerulopathy proved by histology and serology Age 15 60 years, sex free Exclusion Criteria: Serum creatinine > 500 umol/l Severe viral infection(HBV, HCV, CMV) within 3 months of first randomization or known HIV infection Congenital or acquired immunodeficiency Patients with severe infection or central nervous system symptoms Immediately life-threatening organ manifestations (e.g. lung haemorrhage or massive gastro-intestinal bleeding, heart failure due to pericarditis or myocarditis, liver dysfunction measured on at least 2 separate occasion)

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: immunoadsorption<br> | Procedure: immunoadsorption<br>* immunoadsorption<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the efficacy of immunoadsorption in the treatment of lipoprotein glomerulopathy. |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety of immunoadsorption in the treatment of lipoprotein glomerulopathy. |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lipoprotein glomerulopathy, treatment, immunoadsorption, apolipoprotein E
Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
The study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access reconstruction rate, and pharmacoeconomic analysis.

Official Title
-----------------
Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

Conditions
-----------------
Hemodialysis, Hyperphosphatemia, Cardiovascular Events

Intervention / Treatment
-----------------
* Drug: Sevelamer HCl
* Drug: Calcium-based phosphate binder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females aged between 18-70 years old Subject with hyperphosphatemia (5.5 - 8.5 mg/dL) at both WK(-2) and WK0 On stable TIW hemodialysis for 3 months or longer Exclusion Criteria: Patients with hypercalcemia (corrected serum calcium > 10.5 mg/dL) Any of the following abnormalities: ALT or AST > 3X ULN; iPTH > 1000 or < 150 pg/mL History of dysphagia or swallowing disorders History of GI motility disorder or GI bleeding within 3 months prior to entry

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sevelamer HCl<br>Sevelamer HCl regular treatment 1-3 tablets TID | Drug: Sevelamer HCl<br>* Non-metal phosphate binder<br>* Other names: Renagel Tablets;|
| Active Comparator: Calcium-based binder<br>Calcium-based phosphate binder (either CaCO3 or Ca acetate) administered 1-3 tablets TID | Drug: Calcium-based phosphate binder<br> <br> * Other names: Calcium acetate;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite end-point of Ca, P, Ca*P within K/DOQI recommendation |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline, Ca, P, Ca*P |  | 12 months | 
| Change from baseline, lipid profile |  | 12 months | 
| Change from baseline, CRP |  | 12 months | 
| Change from baseline, iPTH (stragified) |  | 12 months | 
| Change from baseline, homocysteine, folate and Vit B12 |  | 12 months | 
| CV-related event rate (OPD admission and hospitalization) |  | 12 months | 
| Comparison of medical-related expenses between group |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Phosphate binder